Skip to content

Intraoperative MRI-guidance in Frameless Stereotactic Biopsies

The Safety and Effectiveness of Low Field Intraoperative MRI-guidance in Frameless Stereotactic Biopsies of Brain Tumours - a Prospective Randomized Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01779219
Enrollment
42
Registered
2013-01-30
Start date
2009-06-30
Completion date
2015-10-31
Last updated
2016-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Brain Tumour

Keywords

intraoperative magnetic resonance, stereotactic biopsy, brain tumor, frameless stereotaxy, image-guided neurosurgery

Brief summary

Background: The aim of the study was to assess the safety and effectiveness of stereotactic brain tumour biopsy (STx biopsy) guided by low-field intraoperative MRI (iMRI) in comparison with its frameless classic analogue based on a prospective randomized trial. Patients are prospectively randomized into a low-field iMRI group and a control group that undergo a frameless STx biopsy. The primary endpoints of the analysis are: postoperative complication rate and diagnostic yield, and the secondary endpoints: length of hospital stay and duration of operation.

Detailed description

INTRODUCTION Stereotactic brain biopsy (STx biopsy) offers a relatively straightforward, accurate and safe method of obtaining diagnostic tissue. Frameless computer-based neuronavigation is now widely used in brain tumor surgery. It has many advantages over frame-based techniques and provides similar accuracy to the rigid frame. One of the methods applied to improve diagnostic yield and safety is the usage of intraoperative magnetic resonance imaging (iMRI), proposed by Bernays et al. in 2002. Besides the obvious indications given in previous papers, including STx biopsy of very small, deeply localized or cystic lesions, iMRI guidance is particularly useful in two cases. The first one is when a satisfactory 3D volume modality cannot be obtained during preoperative high-field diagnostic MR imaging. When using iMRI there is no need to perform preoperative 3D imaging of any kind and manually register the patient's head in a neuronavigation system before the operation, which helps to significantly improve the workflow. In our study the total amount of patients with insufficient neuroimaging - admitted from outside medical centers - is over 30%. The second case is for teaching purposes - frameless iMRI guided STx biopsy, is relatively uncomplicated and technically straightforward and can be introduced as the first procedure during training in neurosurgical intraoperative imaging. Although the usefulness of ultra-low-field iMRI in STx biopsy was subsequently confirmed by other authors, according to our knowledge no previous published studies have compared iMRI to preoperative MRI for brain tumor biopsy according to evidence-based medicine guidelines (EBM). Though this method has been subject to slight criticism, it has been consequently applied in neurosurgical daily practice in recent years. The aim of our study was to verify the safety and effectiveness of the STx biopsy guided by low-field iMRI in comparison with its frameless classic analogue basing on a prospective randomized parallel-group, controlled trial. In the current paper we present the study design and results of the interim analysis. MATERIAL AND METHODS Patients Patients who are - following contemporary recommendations - scheduled to undergo STx biopsy, are prospectively recruited for the study. Each patient sign a written consent to participate in the study. Inclusion criteria The inclusion criteria were as follows: male and female patients ≥ 18 years with supratentorial brain tumor scheduled to undergo STx biopsy. The estimated number of patients needed to reveal the difference of over 5% between primary endpoints' - diagnostic yield and complications ratio - at the level of significance 0.05 and power 80% was 465 per each arm. Exclusion criteria Patients unable to provide informed consent and those with metal implants which could prevent or influence the head MR study were excluded from the study. Allocation Patients were prospectively allocated by minimization according to demographic (gender, age) and epidemiologic data (preoperative Eastern Cooperative Oncology Group Performance Status-ECOG- a scale providing information about neurological and social status of a patient with oncological disease, maximum tumor diameter, presence of contrast enhancement, independent risk factors of hemorrhage - basal and thalamic localization and preoperative diabetes) into the iMRI and the control group. Intervention After being transferred to the operating room each patient was sedated with an intravenous infusion of Remifentanil with passive oxygen therapy and monitoring of vital functions. Additionally, the sites of head holder pins and skin incision were anaesthetized with 1% Lignocaine. All biopsies in both groups were performed via a 6 mm burr-hole with the use of the Vertec system (Medtronic Navigation, Louisville, CO, USA). A passively navigated side cut 2.2 mm biopsy needle was used. All operations were performed by one of the three first authors. In the iMRI-guided group the head of each patient was immobilized with a 3-pin iMRI-compatible head holder. The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures. Subsequently, after the patient's positioning, the preoperative reference examination was routinely carried out (T1+gadolinum, T2 or FLAIR weighted - depending on the pathology, axial 4 mm scans). Images were automatically transferred into the neuronavigation system (StealthStation, Medtronic Navigation, Louisville, CO, USA). The entry point, target and optimal biopsy trajectory were then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples (4 from the central and another 4 from the marginal part of the tumor) were collected according to the modified protocol described by Shooman et al., which made use of intraoperative histopathological examination obsolete. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) was routinely performed to confirm and document the proper targeting and - as proposed by Bernays et al. - to exclude postoperative hyperacute intraparenchymal bleeding. A frameless STx biopsy was performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA). Following surgery the specimens were sent for independent histopathological analysis. Postoperative care Postoperative care was conducted according to standard protocols and clinical guidelines. A postoperative follow-up head CT was subsequently performed 4 to 6 hours after each procedure. All patients were followed up with a clinical examination 2 weeks postoperatively performed by an independent and blinded for the allocation investigator. Data collection Demographic and epidemiological data were collected prospectively. The primary endpoints were: the ratio of acute postoperative complications and the diagnostic yield. The presence of acute postoperative complication was noted if any of following findings was noted: (wound site infection up to two weeks after the operation, a new neurological deficit developed up to 24 hours following the operation and present in a follow up clinical examination 2 weeks postoperatively), intraparenchymal hematoma with radiological or clinical signs of the intracranial expansion.) and the diagnostic yield. The diagnostic yield was expressed according to the literature as a percentage of patients in whom the histopathological diagnosis was possible on the basis of the biological material obtained during the operation. Secondary endpoints included: the preoperative (LOSpre), postoperative (LOSpost) and total length of hospital stay (LOS) as well as the preparation (Tprep), operation (Top) and total operating room (TOR) time. The LOS and T were routinely measured and recorded in the central hospital files by the independent staff.

Interventions

DEVICEiMRI-guided brain tumour biopsy

The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.

DEVICEStereotactic frameless brain tumour biopsy

The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).

Sponsors

Wroclaw Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* male and female patients ≥ 18 years * supratentorial brain tumour * scheduled to undergo STx biopsy

Exclusion criteria

* patients unable to provide informed consent * metal implants which could prevent or influence the head MR study

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Presenting With ComplicationsPatients were followed for the duration of hospital stay (average 2 days) and again 2 weeks after the operation.The presence of acute postoperative complication is noted if any of following findings is present: wound site infection up to two weeks after the operation, a new neurological deficit developed up to 24 hours following the operation and present in a follow up clinical examination 2 weeks postoperatively, intraparenchymal hematoma with radiological or clinical signs of the intracranial expansion.
Diagnostic YieldFor each patient 2 weeks after the operationThe diagnostic yield is expressed as the number of patients in whom the histopathological diagnosis was made based of the biological material obtained during the operation.

Secondary

MeasureTime frameDescription
Length of Hospital StayFrom date of hospitalization until the date of discharge, assessed up to 2 days.The preoperative (LOSpre), postoperative (LOSpost) and total length of hospital stay (LOS)
TimeFrom moment of the transfer to the OR until the moment of transfer out of it, assessed on the day of operation.the preparation (Tprep), operation (Top) and total operating room (TOR) time

Countries

Poland

Participant flow

Participants by arm

ArmCount
iMRI
The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet is used in all procedures. Subsequently, after the patient's positioning, the preoperative reference examination is routinely carried out (T1+gadolinum, T2 or FLAIR weighted - depending on the pathology, axial 4 mm scans). The entry point, target and optimal biopsy trajectory are then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples (4 from the central and another 4 from the marginal part of the tumour) are collected. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) is routinely performed to confirm and document the proper targeting and to exclude postoperative hyperacute intraparenchymal bleeding. Stereotactic intraoperative magnetic resonance (iMRI)-guided frameless brain tumour biopsy: The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with was used in all procedures.
21
Non-iMRI
A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA). Stereotactic frameless brain tumour biopsy: The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
21
Total42

Baseline characteristics

CharacteristiciMRINon-iMRITotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
4 Participants6 Participants10 Participants
Age, Categorical
Between 18 and 65 years
17 Participants15 Participants32 Participants
Age, Continuous52 years
STANDARD_DEVIATION 17
55 years
STANDARD_DEVIATION 15
54 years
STANDARD_DEVIATION 16
Basal localization
basal localisation of the tumor
7 participants9 participants16 participants
Basal localization
non-basal localisation of the tumor
14 participants12 participants26 participants
Diabetes
Diabetes not recorded
15 participants15 participants30 participants
Diabetes
Diabetes recorded
6 participants6 participants12 participants
ECOG Performance Status2 units on a scale2 units on a scale2 units on a scale
Maximum tumour diameter48 mm
STANDARD_DEVIATION 19
54 mm
STANDARD_DEVIATION 18
51 mm
STANDARD_DEVIATION 18
Region of Enrollment
Poland
21 participants21 participants42 participants
Sex: Female, Male
Female
8 Participants9 Participants17 Participants
Sex: Female, Male
Male
13 Participants12 Participants25 Participants
Thalamic localization
extra-thalamic localisation of the tumor
19 participants17 participants36 participants
Thalamic localization
thalamic localisation of the tumor
2 participants4 participants6 participants
Tumour enhancement
Enhancement noted
16 participants13 participants29 participants
Tumour enhancement
No enhancement noted
5 participants8 participants13 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 210 / 21
serious
Total, serious adverse events
0 / 210 / 21

Outcome results

Primary

Diagnostic Yield

The diagnostic yield is expressed as the number of patients in whom the histopathological diagnosis was made based of the biological material obtained during the operation.

Time frame: For each patient 2 weeks after the operation

ArmMeasureValue (NUMBER)
iMRIDiagnostic Yield20 participants
Non-iMRIDiagnostic Yield20 participants
p-value: 1Fisher Exact
Primary

Number of Participants Presenting With Complications

The presence of acute postoperative complication is noted if any of following findings is present: wound site infection up to two weeks after the operation, a new neurological deficit developed up to 24 hours following the operation and present in a follow up clinical examination 2 weeks postoperatively, intraparenchymal hematoma with radiological or clinical signs of the intracranial expansion.

Time frame: Patients were followed for the duration of hospital stay (average 2 days) and again 2 weeks after the operation.

Population: Complications assessed: Haematoma, Neurological deterioration, Infection

ArmMeasureValue (NUMBER)
iMRINumber of Participants Presenting With Complications0 participants
Non-iMRINumber of Participants Presenting With Complications1 participants
p-value: 1Fisher Exact
Secondary

Length of Hospital Stay

The preoperative (LOSpre), postoperative (LOSpost) and total length of hospital stay (LOS)

Time frame: From date of hospitalization until the date of discharge, assessed up to 2 days.

ArmMeasureGroupValue (MEDIAN)
iMRILength of Hospital StayTotal length of hospital stay5 days
iMRILength of Hospital StayThe length of preoperative hospital stay3 days
iMRILength of Hospital StayThe length of postoperative hospital stay2 days
Non-iMRILength of Hospital StayTotal length of hospital stay7 days
Non-iMRILength of Hospital StayThe length of preoperative hospital stay4 days
Non-iMRILength of Hospital StayThe length of postoperative hospital stay2 days
Comparison: Total length of hospital stayp-value: 0.16Wilcoxon (Mann-Whitney)
Comparison: Length of the preoperative hospital stayp-value: 0.73Wilcoxon (Mann-Whitney)
Comparison: Length of the postoperative hospital stayp-value: 1Wilcoxon (Mann-Whitney)
Secondary

Time

the preparation (Tprep), operation (Top) and total operating room (TOR) time

Time frame: From moment of the transfer to the OR until the moment of transfer out of it, assessed on the day of operation.

ArmMeasureGroupValue (MEAN)Dispersion
iMRITimeTotal OR time111 minutesStandard Deviation 24
iMRITimeTime of preparation53 minutesStandard Deviation 22
iMRITimeTime of the operation60 minutesStandard Deviation 26
Non-iMRITimeTotal OR time78 minutesStandard Deviation 29
Non-iMRITimeTime of preparation34 minutesStandard Deviation 20
Non-iMRITimeTime of the operation44 minutesStandard Deviation 20
Comparison: Total OR timep-value: <0.001Wilcoxon (Mann-Whitney)
Comparison: Time of preoperative preparationsp-value: 0.004Wilcoxon (Mann-Whitney)
Comparison: Time of the operation (skin-to-skin)p-value: 0.024Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026